PLUS THERAPEUTICS INC PSTV 深 滬
等待開盤 06-25 09:30:00 美东时间
3.96
-0.120
-2.94%
華盛通- 最 高4.18
- 今 開4.07
- 成交量 9.64万股
- 最 低 3.90
- 昨 收 4.08
- 總市值 2726.02万
- 52周最高 23.425
- 市盈率 靜 --
- 換手率 1.40%
- 52周最低 2.90
- 委 比 -40.83%
- 總股本 688.39万
- 歷史最高 8583.75
- 量 比 0.41
- 振 幅 6.86%
- 歷史最低 3.225
- 每 手 1
- 風險率 4.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
06-08 21:52
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex June 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Allstate and Teleflex on Monday. HIGHLIGHTS * Adobe Inc ADBE.O : TD Cowen cuts target price to $285 from $310
06-08 16:01
Plus Therapeutics Launches New At-The-Market Equity Program
An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 1,...
06-06 06:26
Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous
06-04 19:32
Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-26 19:35
Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology
Partnership to deliver a novel AI-native integrated CNS oncology platformPlatform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision
05-19 19:34
Plus Therapeutics Stockholders Back Directors and Incentive Plan
Plus Therapeutics ( ($PSTV) ) has shared an update. Plus Therapeutics, Inc. hel...
05-16 06:50
Plus Therapeutics Q1 EPS $(1.05) Misses $(0.85) Estimate, Sales $1.028M Beat $974.000K Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.85) by 23.53 percent. This is a 96.48 percent increase over losses of $(29.86) per share
05-16 04:10
Plus Therapeutics Subsidiary Gets Enrolled In Medicare Program, Receives Provider Transaction Access Number From Centers For Medicare & Medicaid Services
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-07 19:33
